Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1371-1372, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morris, L. F.
Right arrow Articles by Braunstein, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, L. F.
Right arrow Articles by Braunstein, G. D.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:1371-1372.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

Interlaboratory Comparison of Thyroglobulin Measurements for Patients with Recurrent or Metastatic Differentiated Thyroid Cancer

Lilah F. Morris1, Alan D. Waxman2 and Glenn D. Braunstein1a

Departments of
1 Medicine, and
2 Nuclear Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048

aAddress correspondence to this author at: Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Suite 2119, Los Angeles, CA 90048. Fax 310-423-0437; e-mail braunstein@cshs.org.

The first 20% of the full text of this article appears below.


To the Editor:

Serum thyroglobulin (Tg) is a tumor marker for persistent and recurrent thyroid cancer (1). However, there are technical limitations of Tg measurements by both RIA and two-site immunometric assays, and Tg results vary among laboratories (1)(2). Some of the discrepancy is likely linked to Tg autoantibody (TgAb) interference as TgAb is detectable by RIA in 18–40% of patients with differentiated thyroid cancer (3)(4). Failure to use the same Tg standard, preferably International Standard CRM-457, is potentially another source of interlaboratory differences in results (5)(6).

In January 1999, we implemented a protocol by which we administer rhTSH (Thyrogen; Genzyme Transgenics Corporation) to patients with thyroid cancer. Serum Tg is measured before and 72 h after 2 days of rhTSH administration. University of Southern California (USC) Endocrine Services Section served as the central laboratory for the original Thyrogen protocol study sites from which the recommendations concerning the interpretation of rhTSH-stimulated Tg concentrations were derived (7). . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al.
Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti
Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.